ライフサイエンスコーパス: occult blood

1 t were processed for the evaluation of fecal occult blood.

2 nced neoplasia had a positive test for fecal occult blood.

3 (EPO) levels, and stool and urine tests for occult blood.

4 for fecal leukocytes nor an assay for fecal occult blood, alone or in combination, allowed for the r

5 Both annual testing for fecal occult blood and biennial testing significantly reduce m

6 aining in and on the HVE tube was tested for occult blood by the guiac resin method.

7 ts provided a stool specimen for culture and occult blood by the standard methods.

8 d EAEC in DNA extracted from stools and from occult blood cards.

9 dition to currently available methods (fecal occult blood, flexible sigmoidoscopy, colonoscopy, and d

10 for colorectal cancer recommend annual fecal occult blood (FOB) testing for adults aged 50 years and

11 There is growing evidence that faecal-occult-blood (FOB) screening may reduce colorectal cance

12 Patients with faecal occult blood, haematochezia, iron-deficiency anaemia, or

13 cult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colore

14 cal cards that was used for the detection of occult blood is of use in identifying diarrheagenic E. c

15 this effect results from possible increased occult blood loss and a cytokine-mediated effect on SF i

16 tric ulcers, and a higher incidence of fecal occult blood loss.

17 Fecal tests (occult blood, methylation) engender excellent patient co

18 e = 3,520; IRR = 0.87 (0.80-0.96) and Faecal Occult Blood Number eligible = 6,566; 0.86 (0.78-0.94).

19 etter screening compliance compared to fecal occult blood or endoscopic screening.

20 pg/ml (odds ratio [OR]: 7.3), positive fecal occult blood (OR: 13.2), hemoglobin < or =90 g/l (OR: 6.

21 tion of hematochezia (19%) or positive fecal occult blood test (15%).

22 ry care providers use only the digital fecal occult blood test (FOBT) as their primary screening test

23 ing test for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low lev

24 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) scr

25 1.38; 95% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than th

26 165.19), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

27 ical smear test, 2) a mammogram, 3) a faecal occult blood test and 4) a prostate specific antigen tes

28 rs (for example, simplifying access to fecal occult blood test cards), or made system-level changes (

29 anol, RNAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test t

30 early cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

31 Consecutive patients with a positive faecal occult blood test or previous adenomas undergoing survei

32 agnostic indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57),

33 ies, these guidelines recommend annual fecal occult blood test screening plus periodic flexible sigmo

34 assing the first screening round of a faecal occult blood test screening programme in a single geogra

35 persons who have positive results on a fecal occult blood test should have a full colonic examination

36 lonoscopy, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 pers

37 colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55

38 ography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the mu

39 the sensitivity and specificity of the fecal occult blood test.

40 Combined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 perc

41 in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons

42 nsitivity of one-time screening with a fecal occult-blood test plus sigmoidoscopy.

43 One-time screening with both a fecal occult-blood test with rehydration and sigmoidoscopy fai

44 40%), blood glucose measurement (41%), fecal occult blood testing (39%), and chest radiography (36%),

45 creening by fecal DNA testing (F-DNA), fecal occult blood testing (FOBT) and/or sigmoidoscopy, or col

46 d mammography, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, flexibl

47 per year of life saved), using annual fecal occult blood testing (FOBT) combined with flexible sigmo

48 lonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonosc

49 opy plus either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical test

50 gy for white men was annual rehydrated fecal occult blood testing (FOBT) plus sigmoidoscopy (followed

51 ikely to have negative attitudes about fecal occult blood testing (FOBT), but not about flexible sigm

52 f once-only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

53 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemic

54 f biennial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-sp

55 Screening Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

56 the results of tests for inflammation (stool occult blood testing [Hemoccult], fecal leukocytes, feca

57 ded to improve patient compliance with fecal occult blood testing and colorectal cancer screening in

58 d clinical trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

59 Combining fecal occult blood testing and sigmoidoscopy may decrease mort

60 d with sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy

61 creened population within 1 year using fecal occult blood testing followed by diagnostic colonoscopy

62 on screening every 3 years plus annual fecal occult blood testing had an ICER of more than $100,000 p

63 istory of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoi

64 Fecal occult blood testing is a popular screening test because

65 If occult blood testing is done, clinicians must decide how

66 positives and high false negatives of fecal occult blood testing lead to high costs and low cost-eff

67 cancer was detected by screening using fecal occult blood testing or evaluation of symptoms.

68 Fecal occult blood testing or flexible sigmoidoscopy was order

69 diagnostic yield supported the use of fecal occult blood testing plus sigmoidoscopy.

70 t age 65) or the combination of annual fecal occult blood testing with sigmoidoscopy every 5 years ar

71 reasonable substitutes for traditional fecal occult blood testing, although modeling may be needed to

72 ed trials support the use of screening fecal occult blood testing, and case-control studies support t

73 Screening with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT)

74 favorably with reported performance of fecal occult blood testing, flexible sigmoidoscopy, and barium

75 3 years, or every 5 years with annual fecal occult blood testing, had an ICER of less than $55,600 p

76 g have illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

77 underwent comprehensive screening with stool occult blood testing, standard upper gastrointestinal en

78 elevant to optimizing the technique of fecal occult blood testing.

79 ears to be lower than that with guaiac fecal occult blood testing.

80 aou smears, cholesterol screening, and fecal occult blood testing.

81 y exists for widespread screening with fecal occult blood testing.

82 Fecal occult-blood testing and sigmoidoscopy have been recomme

83 returned the three specimen cards for fecal occult-blood testing and underwent a complete colonoscop

84 Although fecal occult-blood testing is the only available noninvasive s

85 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality pers

86 In randomized trials, fecal occult-blood testing reduces mortality from colorectal c

87 The use of either annual or biennial fecal occult-blood testing significantly reduces the incidence

88 cards from three consecutive days for fecal occult-blood testing, which were rehydrated for interpre

89 r to annual or biennial screening with fecal occult-blood testing.

90 orectal cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces disease-specific morta

91 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

92 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colore

93 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or c

94 confidence interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53), screen

95 When used for screening, fecal occult blood tests have positive results about 1% to 16%

96 Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality

97 ices Task Force endorse screening with fecal occult blood tests or sigmoidoscopy.

98 , with less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonosco

99 78 healthy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor h

100 alth status using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years

101 nformation that can be used to perform fecal occult blood tests, interpret the results of those tests

102 A number of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast bariu

103 etter performance characteristics than fecal occult blood tests.

104 ged 80-84 years in average health with fecal occult blood tests.

105 nal bleeding, as evidenced by positive fecal occult blood tests.

106 ge-matched men and women with negative fecal occult-blood tests and no family history of colon cancer

107 In a group of patients with positive fecal occult-blood tests who were referred for further evaluat

108 se a positive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gast

109 A set of three fecal occult-blood tests--Hemoccult II; Hemoccult II Sensa, a

110 h subjects who had a negative test for fecal occult blood, the relative risk of advanced neoplasia in

111 Fecal occult blood was detected by standard guaiac-based tests

112 at least one stool specimen containing fecal occult blood who were referred for further evaluation.

113 Of the 409 patients with fecal occult blood who were referred, 310 were potentially eli